Latest news for Toronto-Dominion Bank (OTC:TDBKF) Stock

Toronto-Dominion is one of Canada's two largest banks and operates three business segments: Canadian retail banking, US retail banking, and wholesale banking. The bank's US operations span from Maine to Florida, with a strong presence in the Northeast. It also has a 13% ownership stake in Charles Schwab.

Non Cum Red Pfd Registered Shs -A- Series -7-

TORONTO DOMINION BK PFD 7 by Toronto Dominion Bank (ON)

The Toronto-Dominion Bank

STK Steakhouse brings its unrivaled VIBE dining experience to Canada, overlooking Niagara Falls
This location is the 30th STK Steakhouse in operation; the new, licensed location is part of the Company's asset light growth strategy
The ONE Group Hospitality, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STKS#NASDAQ">STKS</a>) today announced the recent opening of the newest <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fstksteakhouse.com%2F&amp;esheet=54158249&amp;newsitemid=20241126821548&amp;lan=en-US&amp;anchor=STK+Steakhouse&amp;index=1&amp;md5=88a8fc4bbddacd592e33537cb14b7a88">STK Steakhouse</a> with beautiful views of Niagara Falls, on the Canadian side. Located at 6700 Fallsview Blvd., the new restaurant offers VIBE dining at its finest with incredible views and is situated within the Embassy Suites Hotel. The location offers elevated culinary curations, world-famous cocktails and live music spun by renowned DJs. The opening of STK Niagara Falls offers a new location for locals and tourists alike for sought-after views and an upscale dining experience.

News

Global

STKS

The ONE Group Hospitality, Inc. Opens New STK Niagara Falls Location;  Location Is The 30th STK Steakhouse In Operation; The New, Licensed Location Is Part Of The Co's Asset Light Growth Strategy

On Tuesday, Amgen&nbsp;Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) stock fell during the premarket session after the company released long-anticipated data from the Phase 2 study of MariTide (maridebart cafraglutide, formerly AMG 133) <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n42185604/amgen-announces-robust-weight-loss-with-maritide-in-people-living-with-obesity-or-overweight-at-52" rel="noreferrer noopener">in obese patients</a>.
The company said that MariTide demonstrated up to ~20% average weight loss at one year (52 weeks) without a weight loss plateau, indicating the potential for further weight loss beyond 52 weeks.
Amgen&#8217;s stock dropped as the results seemed to fall short of Wall Street&#8217;s high expectations. CNBC noted that analysts had hoped MariTide would achieve at least 20% weight loss in the Phase 2 trial, with some <a target="_blank" href="https://www.cnbc.com/2024/11/26/amgen-says-weight-loss-drug-maritide-caused-up-to-20percent-weight-loss-after-a-year.html" rel="noreferrer noopener">aiming</a> for as much as 25%.
The study also showed that a subset of patients who typically lose less weight on GLP-1 therapies achieved up to ~17% average weight loss without a weight loss plateau, lowering their average hemoglobin A1C (HbA1c) by up to 2.2 percentage points at week 52.
MariTide also demonstrated improvements in cardiometabolic parameters, including blood pressure, triglycerides, and high-sensitivity C-reactive protein (hs-CRP) across doses. There were no significant increases in free fatty acids.
There was no association between the administration of MariTide and bone mineral density changes.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41950871/amgen-defends-its-investigational-monthly-weight-loss-injection-after-analyst-cites-maritides-impact-on-bone-density" rel="noreferrer noopener">Amgen Defends Its Investigational Monthly Weight Loss Injection After Analyst Cites MariTide&#8217;s Impact on Bone Density</a>
The most common side effects were gastrointestinal, including vomiting, nausea, and constipation. Amgen said the discontinuation rate in the dose escalation arms due to any AE was ~11% and less than 8% for GI-related events. No additional safety signals were identified.
In a separate ongoing Phase 1 pharmacokinetic study, additional dosing regimens have been evaluated in a planned preliminary analysis.
The ongoing Part 2 of the Phase 2 study is investigating MariTide beyond 52 weeks to evaluate further weight loss with continued treatment, weight maintenance through less frequent or lower dosing and durability of weight loss after discontinuation of MariTide.
MariTide is expected to be delivered as a single dose in a handheld, autoinjector device with a monthly or less frequent single-injection administration.
Amgen is also advancing its obesity pipeline, including oral and injectable approaches composed of incretin and non-incretin mechanisms.
Price Action: AMGN stock is down 11.6% at $259.88 during the premarket session at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/42188320/best-buy-says-q3-sales-little-softer-than-expected-on-lower-demand-for-appliances-and-gaming-trims-annual-forecast" target="_blank" rel="noreferrer noopener">Best Buy Says Q3 Sales &#8216;Little Softer Than Expected&#8217; On Lower Demand For Appliances And Gaming, Trims Annual Forecast</a></li>
</ul>
Photo via Shutterstock.

Biotech

Equities

Large Cap

Health Care

Movers

Trading Ideas

General

AMGN

Amgen Reveals Data From Closely Watched Monthly Obesity Drug, With Weight Loss Of Up To 20% At One Year And No Plateau

WIIM

M&T Bank shares are trading lower. The stock may be moving on continued weakness following a Citigroup ratings downgrade from Buy to Neutral on Monday.

Truist Securities analyst Patrick Scholes maintains Marriott Vacations (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VAC#NYSE">VAC</a>) with a Buy and raises the price target from $139 to $142.

Price Target

Analyst Ratings

Truist Securities Maintains Buy on Marriott Vacations, Raises Price Target to $142

FDA Marketing Authorization Decision on Early Stage-Low Risk Breast Cancer Expected in Q1 2025
Conference call to be held today at 10:00 am Eastern Time
CAESAREA, Israel, Nov. 26, 2024 /PRNewswire/ -- <a href="https://icecure-medical.com/">IceCure Medical Ltd.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICCM#NASDAQ">ICCM</a>) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today reported financial results as of and for the nine months ended September 30, 2024. Sales of ProSense&#xAE; consoles and disposable probes increased by 36%. Gross profits increased by 41%, while non-GAAP gross profits grew by 104%. Gross margins increased to 43%, while non-GAAP gross margin increased to 40%, compared to 27% in the same period in 2023].

ICCM

IceCure Medical Reports 36% Sales Growth In The First 9-Months Of 2024 Driven By Global Adoption Of ProSense Cryoablation; FDA Marketing Authorization Decision On Early Stage-Low Risk Breast Cancer Expected In Q1 2025

Legal

NCPL

Netcapital's Netcapital Securities Subsidiary Receives Approval To Become A FINRA-Member Broker-Dealer

BTC Digital Ltd. ("BTCT"or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTCT#NASDAQ">BTCT</a>), a global leader in Bitcoin (BTC) mining, announced today that it is actively seeking business opportunities in Arkansas, Tennessee, Georgia, and Missouri to further expand the scale and number of its mining facilities. This initiative aims to meet the growing computational power demands of both the company and the market while fulfilling its strategic commitment to sustainability.
BTCT is exploring various approaches, including building new facilities, acquiring existing mines, and forming strategic joint ventures with local businesses or institutions, to achieve a stable, long-term, and sustainable energy supply. The Company expects that these measures will not only strengthen BTCT's market position in the Bitcoin mining sector but also help the Company build a forward-looking and competitive computational power ecosystem.

BTCT

BTCT  Announces It Is Actively Seeking Business Opportunities In Arkansas, Tennessee, Georgia, And Missouri To Further Expand The Scale And Number Of Its Mining Facilities; Initiative Aims To Meet The Growing Computational Power Demands Of Both The Company And The Market While Fulfilling Its Strategic Commitment To Sustainability

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Markets

$BTC

BNZI

Banzai International Approves Purchase Of Bitcoin Comprising Of 10% Of Corporate Treasury Account

Tenet Healthcare shares are trading lower. The stock may be moving on continued weakness following a Wells Fargo ratings downgrade and price target cut on Monday.

Truist Securities analyst Patrick Scholes maintains Hilton Grand Vacations (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HGV#NYSE">HGV</a>) with a Buy and lowers the price target from $52 to $51.

Truist Securities Maintains Buy on Hilton Grand Vacations, Lowers Price Target to $51

Collaboration to Revolutionize Consumer Engagement at Retail Point-of-Sale
BARTLETT, Tenn., Nov. 26, 2024 /PRNewswire/ -- <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4311751-1&amp;h=2178492921&amp;u=http%3A%2F%2Fwww.surgepays.com%2F&amp;a=SurgePays%2C+Inc.">SurgePays, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SURG#NASDAQ">SURG</a>) ("SurgePays" or the "Company"), a technology and telecommunications company, has completed the integration of its&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4311751-1&amp;h=1268366785&amp;u=https%3A%2F%2Fclearline.me%2F&amp;a=ClearLine">ClearLine</a>&nbsp;point-of-sale marketing platform with <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4311751-1&amp;h=2856196004&amp;u=https%3A%2F%2Fwww.pax.us%2F&amp;a=PAX+Technology">PAX Technology</a>'s lineup of smart payment terminals.

SURG

SurgePays Integrates Its ClearLine Marketing Platform With PAX Smart Payment Terminals, Collaboration To Revolutionize Consumer Engagement At Retail Point-Of-Sale

Truist Securities analyst Neal Dingmann maintains EQT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQT#NYSE">EQT</a>) with a Hold and raises the price target from $32 to $41.

Truist Securities Maintains Hold on EQT, Raises Price Target to $41

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.astronics.com%2F&amp;esheet=54158326&amp;newsitemid=20241126969679&amp;lan=en-US&amp;anchor=Astronics+Corporation&amp;index=1&amp;md5=015f1afd25598de783032dd05ac5024a">Astronics Corporation</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRO#NASDAQ">ATRO</a>) ("Astronics" or the "Company") today announced the pricing of $150 million aggregate principal amount of 5.500% convertible senior notes due 2030 (the "Notes") in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). Astronics also granted the initial purchasers of the Notes an option to purchase up to an additional $15 million aggregate principal amount of the Notes, for settlement within a 13-day period beginning on, and including, the first date on which the Notes are issued. The offering of the Notes is expected to close on December 3, 2024, subject to customary closing conditions.
The Notes will be Astronics' senior unsecured obligations. The Notes will mature on March 15, 2030, unless earlier converted, redeemed or repurchased. The Notes will bear interest at a rate of 5.500% per year, payable semi-annually in arrears on March 15 and September 15 of each year, beginning on March 15, 2025.

Offerings

ATRO

Astronics Corp Announces The Pricing Of $150M Aggregate Principal Amount Of 5.500% Convertible Senior Notes Due 2030

NANO Nuclear Energy And Everstar Announce Outcome Of Three-Month Pilot Project, Say It Has Produced An 'advanced AI-driven compliance solution'

SLNO

Soleno Therapeutics Announces FDA Extension Of Review Period For DCCR Extended-Release Tablets In Prader-Willi Syndrome, New PDUFA Target Action Date Is Mar. 27, 2025

Next-generation satellite equipped with advanced sensor suite and AI-driven data capabilities to deliver critical insights from orbit and expand Sidus Space's on-orbit presence.
Sidus Space (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIDU#NASDAQ">SIDU</a>) (the "Company" or "Sidus"), an innovative, agile space mission enabler, announced the successful completion of the launch processing of LizzieSat&#x2122;-2 at the Astrotech Space Operations facility at Vandenberg Space Force Base in California. LizzieSat&#x2122;-2 has been turned over to SpaceX and is ready for launch on the Bandwagon-2 rideshare mission, which is targeted for no earlier than December of 2024.
LizzieSat&#x2122;-2 was designed and manufactured at Sidus Space's state-of-the-art facility on Florida's Space Coast. The satellite is equipped with an advanced sensor suite that includes AIS, multi-spectral methane detection, and high-resolution visual spectrum sensors, as well as the HEO Holmes Imager, provided by HEO (USA), a subsidiary of Australian-based HEO. The Holmes Imager is a cutting-edge technology that powers HEO Inspect, an in-orbit satellite inspection platform designed for non-Earth imaging (NEI) and the precise characterization of space objects. LizzieSat&#x2122;-2 will provide data through a monthly subscription contract for HEO, further demonstrating Sidus Space's role as a leading provider of multi-mission space-based data solutions.
Leveraging Sidus' proprietary FeatherEdge&#x2122; AI processor, LizzieSat&#x2122;-2 will enable on-orbit data processing for actionable insights, supporting applications such as Space Situational Awareness (SSA), non-Earth Imaging, maritime monitoring, environmental assessments and disaster response.

SIDU

Sidus Space Announces LizzieSat-2 Ready For Launch; Has Been Turned Over To SpaceX And Is Ready For Launch On The Bandwagon-2 Rideshare Mission, Which Is Targeted For No Earlier Than December Of 2024

Truist Securities analyst Jake Bartlett maintains Dave &amp; Buster's Enter (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLAY#NASDAQ">PLAY</a>) with a Buy and lowers the price target from $59 to $56.

PLAY

Truist Securities Maintains Buy on Dave & Buster's Enter, Lowers Price Target to $56

Amid rising tensions over trade policies, Mexico faces a dilemma regarding a potential investment from Chinese electric vehicle manufacturer&nbsp;BYD (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BYDDY#OTC">BYDDY</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BYDDF#OTC">BYDDF</a>). This comes as President-elect&nbsp;Donald Trump&nbsp;<a href="https://www.benzinga.com/24/11/42178994/trump-says-he-will-impose-25-tariffs-on-canada-mexico-on-first-day-of-office-and-extra-tariffs-on-china-until-they-pay-attention">plans&nbsp;to impose a 25%</a> tariff&nbsp;on Mexican goods, raising concerns about the implications of hosting a Chinese EV factory.
What Happened: BYD is in the final stages of planning a new factory in Mexico. The company is negotiating with Mexican state officials to establish the&nbsp;factory near one of the&nbsp;country&#8217;s&nbsp;automotive hubs in central or&nbsp;northern Mexico. However, Trump&#8217;s tariff threats have complicated these plans. 
Mexico, a significant car manufacturing hub, typically welcomes foreign investment for job creation. Yet, officials are wary that a BYD plant might signal to Trump that Mexico is facilitating Chinese companies&#8217; access to the U.S. market, Wall Street Journal <a href="https://www.wsj.com/business/autos/mexico-gets-cold-feet-over-new-chinese-ev-plant-after-trump-win-3b92f1c3">reported</a> on Tuesday.
"At this time, investments from China have to be analyzed with extreme caution," said Eduardo Solís, the former president of the Mexican Association of the Automotive Industry.
"Mexico has to present itself with a business card that says: reliable partner of North America."
See Also:&nbsp;<a href="https://www.benzinga.com/trading-ideas/movers/24/11/42119433/sharkninja-a-china-hustle-based-on-rampant-looting-short-report?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">SharkNinja A &#8216;China Hustle Based On Rampant Looting&#8217;: Short Report</a>
Trump&#8217;s tariff threat is part of broader issues, including immigration and fentanyl smuggling. Mexico is working to assure the U.S. and Canada that it is not a conduit for Chinese goods as talks on the U.S.-Mexico-Canada Agreement are set to begin next year. Eduardo Solís, a former leader of Mexico's automotive industry association, emphasized the need for caution with Chinese investments, stating Mexico must present itself as a reliable North American partner.
Why It Matters: BYD&nbsp;had previously <a href="https://www.benzinga.com/markets/equities/24/09/40693961/chinas-ev-giant-byd-reportedly-delays-mexico-move-eyes-us-election-results-before-big-investment">delayed its investment</a> in Mexico, awaiting the outcome of the U.S. election. The company aims to sell 100,000 electric vehicles in Mexico by 2025, despite potential tariff challenges.&nbsp;BYD&nbsp;plans to reveal the location of its first Mexican factory by <a href="https://www.benzinga.com/news/24/10/41246093/byd-targets-100k-ev-sales-in-mexico-by-2025-as-trump-vows-200-tariffs-on-chinese-made-cars-in-north">the end of the year</a>, with an initial production capacity of 150,000 vehicles.
Trump&#8217;s proposed tariffs are part of a broader strategy to address border issues and drug smuggling, with additional tariffs on Chinese imports until these issues are resolved. 
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/tech/24/11/42111283/elon-musks-starlink-faces-new-competition-as-chinese-satellite-firm-spacesail-enters-brazilian-market?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Elon Musk&#8217;s Starlink Faces New Competition As Chinese Satellite Firm Spacesail Enters Brazilian Market</a></li>
</ul>
Disclaimer: This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.
Image via Shutterstock

BYDDF

BYDDY

Amid Trump's Plans To Impose 25% Tariffs, Mexico Fears BYD New Factory In Country Would Send Wrong Message: 'Investments From China Have To Be Analyzed With Extreme Caution'

Guidance

Best Buy CEO Says Seeing Increasing Stabilization In Electronics Industry, But Not As Linear As Expected At The Start Of The Year; Co. Sees Q4 Comparable Sales To Be In The Range Of Down 3% To Flat

RBC Capital analyst James McGarragle upgrades Russel Metals (TSX:<a class="ticker" href="https://www.benzinga.com/stock/RUS#TSX">RUS</a>) from Sector Perform to Outperform and raises the price target from C$45 to C$51.

Comments

Toronto-Dominion Bank

News

Latest news for Toronto-Dominion Bank (OTC:TDBKF) Stock

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga